Davalintide

Drug Profile

Davalintide

Alternative Names: AC 2307; Second generation amylinomimetic

Latest Information Update: 28 Dec 2012

Price : $50

At a glance

  • Originator Amylin Pharmaceuticals
  • Class Multiprotein complexes; Obesity therapies; Peptides; Proteins
  • Mechanism of Action Amylin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity; Psychiatric disorders

Most Recent Events

  • 25 Dec 2012 Amylin Pharmaceuticals and Takeda terminate their agreement for this programme
  • 24 Feb 2010 Discontinued - Phase-II for Obesity in USA (SC)
  • 24 Feb 2010 Discontinued - Preclinical for Psychiatric disorders in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top